Coenzyme A
In clinical developmentAlso known as 3'-phosphoadenosine-(5')diphospho(4')pantatheine, CoA.
Recent clinical, regulatory, research and industry developments relating to this drug.
The subsystems approach to genome annotation and its use in the project to annotate 1000 genomes.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes5
Journals, researchers & institutions
- Genome biology1
- Nucleic acids research1
- Begley T1
- Butler RM1
- Cao G1
- Chen LL1
- Choudhuri JV1
- Chuang HY1
- Cohoon M1
- de Crécy-Lagard V1
- College of Veterinary Medicine1
- Hubei Key Laboratory of Agricultural Bioinformatics1
- Key Laboratory of Development of Veterinary Diagnostic Products1
- National Key Laboratory of Agricultural Microbiology1
- Novogene Bioinformatics Institute1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials